cyrilzakka/clinical-trials huggingface dataset:
The Effects of Filter During CPET on WOB and Aerosol Particle Concentrations

Due to the concerns of virus transmission during COVID-19 pandemic, multiple respiratory societies postpone or limit pulmonary function test, especially cardiopulmonary exercise test (CPET), as patients may generate large amount of aerosol particles during test but it is conventionally performed without filter. This study aims to investigate the effects of reducing aerosol particle concentrations in the room air during CPET by placing an inline filter, and to assess the effects of filter on the physiologic responses during CPET.

The subject will spend two visits one hour each day (\~ 1 hour) in the PFT lab and will have two separate CPET (Vmax Encore PFT System, Vyaire medical, Mettawa, IL) tests performed by registered pulmonary function technologists. One day the test will be performed with the inline filter during CPET, and the second day the CPET will be performed without a filter. During the test, electrocardiogram (ECG) electrodes will be attached to participants as well as a mask, and their heart rate will be measured for 10 minutes at rest, and then they will ride bicycle for 20 minutes at different levels of intensity. The work rate increment will be the same for both tests. All gas exchange and aerosol particle concentrations measures will be compared with Bland Altman analysis and paired t-testing.

Eligibility Criteria:
Inclusion Criteria:

* Ages 18-65, Male or Female
* Normal exercise tolerance without dyspnea or clinically important limitation of exercise tolerance.

Exclusion Criteria:

* Complicated heart or lung disease
* Pregnancy
* Complex arrhythmias
* Severe Anemia
* Uncontrolled Diabetes, hypertension, or untreated thyroid disease
* Has any of the following symptoms in the last 21 days: sore throat, cough, chills, body aches for unknown reasons, shortness of breath for unknown reasons, loss of smell, loss of taste, fever at or greater than 100 degrees Fahrenheit.
* COVID-19 test positive within 21 days.
* Any Disease that the PI feels will markedly increase the risk of CPET testing
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak

A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to the rest of the world, including Europe and explicitly affects the respiratory system, generating Coronavirus disease 2019 (COVID-19).

This study is a monocentric interventional prospective cohort study. After signing a written informed consent, participants will be recruited for questionnaire completion and blood sampling. Sample storage and analysis will be performed at the laboratory of microbiology of the UZ Brussel.

* To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5.
* To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.


Eligibility Criteria:
Inclusion Criteria:

* Any adult employee of the UZ Brussel who provided a signed informed consent to participate in the study.

Exclusion Criteria:

* UZ Brussel employees whose contract expires within 6 months of study initiation, with the exception of resident trainees (if training continues in another hospital, resident trainees will be asked to perform the last sampling when leaving the UZ Brussel).
* Staff not active during the inclusion period
Comparison of Different EtCO2 Levels in Preventing Postoperative Nausea and Vomiting

We aimed to evaluate the different ETCO2 levels (with the help of ultrasonographic optic nerve sheath diameter) in preventing gynecological laparoscopic surgeons' postoperative nausea induced by intracranial pressure change due to pneumoperitoneum and trandelenburg position.

Although gynecologic laparoscopic surgery is a preferred technique in recent years due to its minimally invasive technique, the incidence of postoperative nausea and vomiting (PONV) is 53-72%. In such operations, intra-abdominal pressure due to trandelenburg position and carbondioxide insufflation causes intra-cranial venous obstruction and intra-cranial pressure increase. In addition, intra-cranial blood flow and ultimately intra-cranial pressure increase due to gravity and increased venous return resistance (peripheral vascular resistance). Intra-cranial CO2 concentration increase results in intra-cranial vascular dilatation, followed by ICP increase. High intracranial pressure may cause an increase in the incidence of PONV after gynecological laparoscopic surgery. Measurement of optic nerve sheath diameter with USG, a noninvasive method for detecting intracranial pressure increases, has been used frequently in intensive care units in recent years. we aimed to evaluate the different ETCO2 levels (during the operation with 10 minute intervals, and also with the help of ultrasonographic optic nerve sheath diameter) in preventing gynecological laparoscopic surgeons' postoperative nausea induced by intracranial pressure change due to pneumoperitoneum and trandelenburg position.

Eligibility Criteria:
Inclusion Criteria:

25-50 age, ASA I / II, BMI: 18-33 kg/m2, operation time: 50-130 min., gynecological laparoscopy

Exclusion Criteria:

In previous operations, Patients with postoperative nausea-vomiting (PONV) history, Smoking, Vehicle stays, Liver and kidney dysfunction, Abnormal fluid electrolyte balance, Gastrointestinal system disease, Preoperative antiemetic drug use, Cerebral disease,dysrhythmia
The Role of Metformin and Colesevelam in Human GLP-1 Secretion

Our primary hypothesis is that bile acid sequestrant colesevelam and the antidiabetic drug metformin potentiates the secretion of the gut hormone glucagon-like peptide 1 (GLP-1).


Eligibility Criteria:
Inclusion Criteria:

* Normal hemoglobin
* BMI \> 23kg/m2
* HbA1c \<9 %
* Informed concent

Exclusion Criteria:

* Liver disease ( aspartate aminotransferase/alanine aminotransferase \>2 × reference value)
* Chronic intestinal disease
* History of liver and / or gallbladder disease
* Nephropathy (se-creatinine \>110 µM and / or albuminuria)
* Insulin or GLP-1-based antidiabetic treatment
* History of cholecystectomy or surgical resection of bowel segment
* BMI \<23kg/m2 or BMI \>35 kg/m2
* Pregnancy
The Effect of Local Anesthesia and Simple Maneuver on Shoulder Pain After Gynecologic Laparoscopy

This prospective, randomized controlled trial was designed to compare the efficacy of a simple maneuver using lower airway pressure (30 cm H2O) and intraperitoneal instillation of bupivacaine, alone or in combination, to reduce shoulder pain after gynecologic laparoscopy.

Patient aged 15-65 years, scheduled for laparoscopic surgery for benign adnexa disease will be eligible for the study. Patients will be excluded from analysis if the procedure requires conversion to a laparotomy, an operative time \> 3 hours, or interpretation of pain is impossible due to serious adverse effects

240 patients will be randomly assigned to one of four groups Upon completion of surgery, the patient is placed in the Trendelenburg position (30 degrees), and one of four procedures is followed. For group A (control), 50 ml of normal saline is instilled under the diaphragm and CO2 is removed by manual deflation of the abdominal cavity through the cannula; For group B, a mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm and CO2 is removed by manual deflation of the abdominal cavity through the cannula; For group C, 50 ml of normal saline is instilled under diaphragm and CO2 was removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O. The anesthesiologist holds the fifth positive pressure inflation for approximately 5 seconds. During these maneuvers, the surgeon will be instructed to ensure that the trocar sleeve valve is fully open to allow the CO2 gas to escape. For group D, patients receive an instillation of a mixture of 50ml solution in combination with the clinical maneuver.

Patients will be given a questionnaire with the pain question represented as a visual analog scale (VAS) preoperatively. Patients will be asked to fill out the questionnaires during the first 24 hours after surgery to determine the frequency and severity of their shoulder pain. All patients are instructed to record the pain scores regarding their shoulder pain only. The degree of postoperative shoulder pain will be assessed using VAS at 1, 6, 12, and 24 hours postoperatively. The VAS, with scores ranging from 0 (no pain) to 10 (excruciating pain), is constructed without numeration, thus allowing patients to mark a point along the scale that best represented their pain at that time.

In addition, the following parameters are recorded on the case report form by the investigators: operative time, blood loss, the length of hospital stay, analgesic use, and incidence of postoperative events.


Eligibility Criteria:
Inclusion Criteria:

* benign adnexa diseases which are scheduled for laparoscopic surgery

Exclusion Criteria:

* The procedure required conversion to a laparotomy, An operative time \> 3 hours, Interpretation of pain was impossible due to serious adverse effects.
A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults

Investigators aim to test the effectiveness of a text-message-based behaivoral intervention in reducing binge drinking among young adults.

Alcohol consumption, especially in the form of heavy episodic drinking (bingeing), is common among young adults. Despite high rates of illness and injury associated with heavy episodic drinking, many young adults are not aware of the risks, few seek help for their drinking and many at-risk are not exposed to prevention-based intervention. Opportunistic screening in hospital Emergency Departments (EDs) tied to behavioral interventions has the potential to prevent future alcohol-related harm among young adults, but efficacy across outcomes has been mixed and large-scale implementation of prevention programs is low. Given the rapidly growing use of cell phone text-messaging (SMS) as a primary form of communication among young adults, SMS could be used to deliver health prevention interventions. We will recruit young adults identified in the ED with hazardous drinking behavior in a 3-arm randomized controlled trial to test the hypothesis that exposure to a 12-week SMS program will result in immediate (3-month) and lasting (6-, and 9-month) decreases in alcohol consumption.

Eligibility Criteria:
Inclusion Criteria:

* AUDIT-C score 3 or more for women and 4 or more for men

Exclusion Criteria:

* Current treatment for psychiatric disease
* Any prior treatment for drug or alcohol use disorder
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the clinical course (occurrence of stroke, major bleeding and mortality) and its correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and pharmacogenetic factors.

Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation treated with direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) to assess the clinical course (occurrence of stroke, other ischemic or bleeding events and mortality) and its correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and pharmacogenetic factors.

Patient selection and follow-up will be performed in 6 public Spanish hospitals: Hospital Universitario de la Princesa, Hospital Universitario La Paz, Hospital Universitario Ramón y Cajal, Fundación Jiménez Díaz, Hospital Gómez Ulla (Madrid) and Hospital Universitario de Burgos (Burgos). To reduce variability, the determination of anticoagulant activity will be performed in the Hematology Service of the Hospital Universitario de Burgos and the measurement of plasma concentrations and genotyping of all patients in the Clinical Pharmacology Service of the Hospital Universitario de la Princesa.

Patients who are to receive or are receiving one of the four DOACs currently available in Spain will be informed about the characteristics of this study and will be asked to sign the consent form for their participation. The treatment or clinical management of these patients at each centre will not be modified. They will be asked three blood samples, coinciding with other tests that will be carried out to monitor their pathology (one blood sample for the study of the effect on coagulation, another for drug quantification in plasma and another for genetic studies) with the only requirement that they must have been treated with the drug for at least one week so that they have spent more than 5 half-lives and are in steady state. The samples will be extracted in the morning, before medication intake (trough concentrations).

Eligibility Criteria:
Inclusion Criteria:

1. Men or women over 18 years of age
2. Patients with non-valvular atrial fibrillation (NVAF).
3. Patients who are going to receive or are receiving treatment with any of the DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for the prevention of stroke and systemic embolism in adult patients with NVAF, according to the drug label.
4. Patients who agree to participate in the study and give their written consent.

Exclusion Criteria:

1. Patients on treatment with other anticoagulants.
2. Patients suffering from a malignant or terminal disease whose life expectancy is less than 6 months.
Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)

The purpose of this study is to evaluate the safety and effectiveness of two approved drugs in lowering high cholesterol when taken together, compared to taking only one of the drugs.

The duration of treatment is 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Elevated cholesterol level

Exclusion Criteria:

* Liver disease
* Known allergies to study drugs
Cognitive Bias Modification for Interpretation Individuals With Chronic Musculoskeletal Pain

Cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign, rather than interpret it as being related to pain. The goal of this randomised controlled trial was to explore the feasibility and potential clinical benefits of CBM-I in people with chronic pain and also healthy, pain-free individuals.

This study investigated whether Cognitive Bias Modification for Interpretation (CBM-I) could reduce negative emotional response to pain and to pain-related images, and whether reductions in interpretation bias (IB) and fear of pain mediated this effect. Participants with chronic musculoskeletal pain (N = 41) were randomised to benign CBM-I or no CBM-I, and healthy participants (N = 41) were randomised to benign CBM-I or pain-related CBM-I. After CBM-I, the study assessed pain-related IB and fear of pain, as well as negative emotional response to exercise-induced pain and images of musculoskeletal pain.

Eligibility Criteria:
Chronic pain group Inclusion criteria

* Experience musculoskeletal pain (pain in muscles, bones, joints, tendons, or ligaments) that has lasted for at least the last 3 months before enrolment in the study
* Have visited a healthcare professional for their pain
* Aged 18-70 years
* Normal or corrected to normal vision
* Fluency in the English language Exclusion criteria
* Any known reading difficulty

Healthy group Inclusion criteria

* Aged 18-70 years
* Normal or corrected to normal vision
* Fluency in the English language Exclusion criteria
* Experience frequent or continuous pain for the past three months before enrolment in the study
* Currently experiencing pain
* Any known reading difficulty
Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults

Adult-Onset Still's disease is a polygenic autoinflammatory disease of unknown etiology. The autoinflammatory character individualizes it from autoimmune autoantibody diseases. Clinically, it results in the classic triad associating hectic fever, evanescent rash and arthritis. Although it is benign in the vast majority of cases, life-threatening complications can occur. By definition, the disease affects adults over 16 years of age, however most experts now agree that the adult form and the pediatric form belong to a pathological continuum: Still's disease. In the absence of a specific biomarker, the diagnosis is still based on clinical and biological criteria, after the exclusion of differential diagnoses.

Classically, three evolutionary profiles of Adult-Onset Still's disease are individualized, depending on the evolution of symptoms over time:

* a monocyclic systemic form (30% of cases) characterized by clear systemic symptoms and in the foreground compared to the articular signs. This form evolves over several weeks to several months (on average 9 months), without exceeding a year. By definition, there is no recurrence;
* a polycyclic systemic form (30% of cases) defined by the occurrence of at least two systemic or joint episodes, separated by clinical remission intervals greater than two months, or even several years. The symptoms of relapses are not always the same as the initial symptoms. The number and severity of relapses is unpredictable and varies widely from patient to patient, but symptoms tend to become less severe over time.
* a chronic form, with predominant joint involvement (40%), resembling seronegative rheumatoid arthritis. Systemic signs are present during the first outbreaks of the disease. Subsequently, rheumatoid arthritis evolves on its own and one can see joint destruction or conversely ankylosing developments such as the classic bilateral, non-erosive fusing carpitis.

There are reasons to believe that the evolving profile of patients has changed since the emergence and generalization of biotherapies. Furthermore, no prognostic factor for the progression of Adult-Onset Still's disease has been found so far. The differences between pediatric and adult forms need to be confirmed and becoming pediatric forms in adulthood is poorly described.

The objective of this study is to set up a regional research database (Auvergne-Rhône-Alpes-Limousin) in order to describe the characteristics, treatment and evolution of patients with Still's disease.


Eligibility Criteria:
Inclusion Criteria:

* children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital

Exclusion Criteria:

* Not applicable
PA4Health Physical Activity App Open Pilot Study for African American Women

Test the acceptability of a smartphone physical activity app for African American women

The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app. They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app.

Intervention components: The intervention components include: tailored daily text intervention text message, educational feature, goal setting and monitoring, and an activity locator that allow participants to enter their zip code and view available resources for physical activity.

Eligibility Criteria:
Inclusion: Eligible participants must:

1. be ages 18-64
2. identify as AA and female
3. own a smartphone
4. be able to provide consent
5. not regularly physically active (i.e. less than 90 mins. of MVPA per week), 6) medically cleared for PA,

7) have a valid email address, and 9) no previous engagement in the study.

Exclusion: Individuals will be excluded if they report:

1. physical limitations to PA engagement
2. significant medical conditions (e.g., heart failure)
3. planned surgery in the next 6 months,
4. pregnant or plan to become pregnant in the next 6 months.
The Effect Of Myofascial Release Technique On Respiratory Parameters in Subjects With Short Hamstring Muscle

The aim of this study was to investigate the effect of myofascial release technique on rib cage mobility, respiratory function, respiratory muscle strength and endurance in patients with hamstring muscle shortness.

Hamstring flexibility is important to maintain activities such as walking and running in daily life. Hamstring muscle shortness, commonly seen in the community, is a risk factor for many musculoskeletal pathologies. Clinical observations have shown that the shortness of the Hamstring muscle causes spinal malalignment. This deterioration of the spine alignment may adversely affect the rib cage expansion. Moreover, considering that the optimal length of the muscles provides optimal contraction, it was found that the spinal malalignment adversely affected the effective contraction of the diaphragm by changing the position of diaphragm. A different view is that, because the fascia functions as a single tissue surrounding the entire body, a restriction in the hamstring muscle can also cause a restriction in distal muscles such as diaphragm through the fascia.

There are many treatment methods used to increase the flexibility of the hamstring muscle. One of these methods is the myofascial release technique. In this technique, which targets both muscle and fascia, applying light and prolonged pressure provides the myo-fascial complex to reach its optimal length, resulting in the optimal function of the muscle. In our best knowledge, no study has evaluated the effect of myofascial release technique on respiratory parameters in patients with hamstring muscle shortness.

Eligibility Criteria:
Inclusion Criteria:

* more than 15 degrees knee flexion angle during popliteal angle test,
* no generalized joint laxity according to Beighton Criteria, and
* no musculoskeletal problems of lower extremities.

Exclusion Criteria:

* history of lower extremity and/or axial skeletal fracture;
* recent muscle, tendon injury in lower extremity;
* history of lumbal disc herniation, arthritic and/or inflammatory disease;
* obesity, diabetes and/or metabolic syndrome;
* history of surgery in the last month,
* using muscle relaxant medication in the last month;
* received manual therapy in the last month